Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04343521
Other study ID # IRB00108666
Secondary ID 1U01AI148069-01
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date November 3, 2020
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by: considering Ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- ABD transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.


Description:

Contemporaneous urban vector control (truck-mounted ultra-low volume spraying, thermal fogging, larviciding) has failed to contain dengue epidemics and to prevent the global range expansion of Aedes-borne diseases (ABDs: dengue, chikungunya, zika). Part of the challenge in sustaining effective ABD control emerges from the remarkable paucity of evidence about the epidemiological impact of any vector control method. Furthermore, the classic deployment of interventions in response to clinical cases fails to account for the important contribution of out-of-home human mobility and asymptomatic infections. The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to follow a population of 4,600 children 2-15 years old randomly allocated to receive either TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by: considering Ae. aegypti behavior to rationally guide insecticide applications; the change to preventive control (pre- ABD transmission season rather than in response to symptomatic cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4702
Est. completion date December 31, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 2 Years to 15 Years
Eligibility Inclusion Criteria: 1. Household Level Inclusion Criteria: - Household is located within the bounds of a study cluster (5x5 city-block clusters). - City block has at least 60% premises that are residential. 2. Individual Level Inclusion Criteria: - 2 or more and up to 15 years of age at the time of initial enrollment - Living in a house that consented to TIRS. Exclusion Criteria: 1. Household Level Exclusion Criteria: - Households where study personnel identify a security risk (i.e., site where drugs are sold, residents are always drunk or hostile) - Sites where no residents spend time during the day (i.e. work 7d a week outside the home).Inability for a resident to provide informed consent. - Non-residential places (e.g., businesses, schools, markets, etc.). 2. Individual Level Exclusion Criteria: - Less than 2 years of age or more than 15 years of age at the time of enrollment. - Not living in a house that consented to TIRS. - Having a medical condition that prevents implementation of study procedures. - Temporary visitor to household - Plans to leave study area within next 12 months

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Targeted Indoor Residual Spraying (TIRS)
Spraying of insecticide Actellic 300CS will start May-June and extend for 1-2 months. Residents will be asked to temporarily leave the house during treatment and wait 0.5-1 h for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed in CDC-Emory-UADY collaboration.

Locations

Country Name City State
Mexico Universidad Autonoma de Yucatan Merida Yucatan

Sponsors (2)

Lead Sponsor Collaborator
Emory University National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Mexico, 

References & Publications (5)

Che-Mendoza A, Gonzalez-Olvera G, Medina-Barreiro A, Arisqueta-Chable C, Bibiano-Marin W, Correa-Morales F, Kirstein OD, Manrique-Saide P, Vazquez-Prokopec GM. Efficacy of targeted indoor residual spraying with the pyrrole insecticide chlorfenapyr against pyrethroid-resistant Aedes aegypti. PLoS Negl Trop Dis. 2021 Oct 4;15(10):e0009822. doi: 10.1371/journal.pntd.0009822. eCollection 2021 Oct. — View Citation

Dzib-Florez S, Ponce-Garcia G, Medina-Barreiro A, Gonzalez-Olvera G, Contreras-Perera Y, Del Castillo-Centeno F, Ahmed AMM, Che-Mendoza A, McCall PJ, Vazquez-Prokopec G, Manrique-Saide P. Evaluating Over-the-Counter Household Insecticide Aerosols for Rapid Vector Control of Pyrethroid-Resistant Aedes aegypti. Am J Trop Med Hyg. 2020 Nov;103(5):2108-2112. doi: 10.4269/ajtmh.20-0515. — View Citation

Dzul-Manzanilla F, Correa-Morales F, Che-Mendoza A, Palacio-Vargas J, Sanchez-Tejeda G, Gonzalez-Roldan JF, Lopez-Gatell H, Flores-Suarez AE, Gomez-Dantes H, Coelho GE, da Silva Bezerra HS, Pavia-Ruz N, Lenhart A, Manrique-Saide P, Vazquez-Prokopec GM. Identifying urban hotspots of dengue, chikungunya, and Zika transmission in Mexico to support risk stratification efforts: a spatial analysis. Lancet Planet Health. 2021 May;5(5):e277-e285. doi: 10.1016/S2542-5196(21)00030-9. — View Citation

Kirstein OD, Ayora-Talavera G, Koyoc-Cardena E, Chan Espinoza D, Che-Mendoza A, Cohuo-Rodriguez A, Granja-Perez P, Puerta-Guardo H, Pavia-Ruz N, Dunbar MW, Manrique-Saide P, Vazquez-Prokopec GM. Natural arbovirus infection rate and detectability of indoor female Aedes aegypti from Merida, Yucatan, Mexico. PLoS Negl Trop Dis. 2021 Jan 4;15(1):e0008972. doi: 10.1371/journal.pntd.0008972. eCollection 2021 Jan. — View Citation

Manrique-Saide P, Dean NE, Halloran ME, Longini IM, Collins MH, Waller LA, Gomez-Dantes H, Lenhart A, Hladish TJ, Che-Mendoza A, Kirstein OD, Romer Y, Correa-Morales F, Palacio-Vargas J, Mendez-Vales R, Perez PG, Pavia-Ruz N, Ayora-Talavera G, Vazquez-Prokopec GM. The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. Trials. 2020 Oct 8;21(1):839. doi: 10.1186/s13063-020-04780-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples living in the core 3x3 city blocks of each cluster. Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses (DENV, CHIKV and ZIKV) in paired acute and convalescent samples for a subset of children living in the core 3x3 city blocks of the cluster. Up to 5 years
Secondary Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses cases in annual surveillance samples Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses (DENV, CHIKV and ZIKV) in annual surveillance samples Up to 5 years
Secondary Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) assessed by RT-PCR Up to 5 years
Secondary Ae. aegypti indoor entomological index adult presence/abundance Ae. aegypti indoor entomological index adult presence/abundance will be calculated. Presence of mosquitoes/house. The higher the value, the worst the outcome. Up to 5 years
Secondary Ae. aegypti indoor entomological index female presence/abundance Ae. aegypti indoor entomological index female presence/abundance will be calculated. Number of mosquitoes/house. The higher the value, the worst the outcome. Up to 5 years
Secondary Ae. aegypti indoor entomological index bloodfed female presence/abundance. Number of bloodfed females per house. The higher the value, the works the outcome. Ae. aegypti indoor entomological index bloodfed female presence/abundance will be calculated Up to 5 years
Secondary Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples living in the entire cluster. Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses (DENV, CHIKV and ZIKV) in paired acute and convalescent samples for a subset of children living in the entire cluster. Up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT05321264 - Educational Intervention to Promote Control Behaviors and Prevention of Dengue N/A
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Enrolling by invitation NCT02016027 - Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting NCT04582474 - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT03803618 - Dengue Effectiveness Study in the Philippines
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1

External Links